GFAP and myeloid sarcoma: In the MS patient group, cerebrospinal fluid GFAP showed the strongest correlation with the number of non-enhancing MRI lesions (Spearman’s rho: 0.544, Fig. 2C) and the duration of disease (Spearman’s rho: 0.472, Fig. 2A).